Semaglutide Explored for Direct Impact on Heart Artery Plaque in Type 2 Diabetes
Semaglutide Treatment On Coronary Progression
Background
Patients living with Type 2 Diabetes face a significantly heightened risk of developing Coronary Artery Disease (CAD), a severe condition driven by atherosclerosis—the progressive accumulation of fatty plaques within the arteries supplying the heart. This plaque buildup can lead to blockages, heart attacks, and strokes. While Semaglutide, a GLP-1 receptor agonist, has demonstrated remarkable efficacy in improving glycemic control and facilitating weight loss, a crucial scientific question remains: does Semaglutide directly influence, slow, or even reverse the progression of existing coronary atherosclerotic plaque?
Study Design
Population
Patients with Type 2 Diabetes and Coronary Artery Disease (CAD) driven by atherosclerosis.
Intervention
Semaglutide, a GLP-1 receptor agonist; dose, route, and duration not specified.
Outcome
Direct influence, slowing, or reversal of existing coronary atherosclerotic plaque progression.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
